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Aims: To evaluate improvement in gestational diabetes (GDM) outcomes for moth-
ers and their offspring induced by education provided to the healthcare team (HCTM)
andwomenwithGDM, plus coordination between primary care units (PCU) and highly
complexmaternity (HCM) facilities.
Methods: Pregnant women with GDM completing control visits from first appoint-
ment until delivery were recruited in participating PCU-HCM, in the cities of Corri-
entes and Buenos Aires; 263 women recruited from 2017 to mid-2018 were assigned
to the control group (CG), and 432 women recruited from mid-2018 to 2019 to the
intervention group (IG). The CG received standardized care/routine management and
follow-up, including basic information on blood glucose monitoring and insulin injec-
tionwhennecessary,whereas the IG received aneducational program targetingHCTM
and women with GDM. These courses included standards of diagnosis, prevention
and treatment of GDM, plus systematic registry of clinical and metabolic indicators
(fasting blood glucose, serum cholesterol and triglyceride). Data on obstetric history,
preeclampsia, gestation-induced hypertension, delivery method and newborn’s body
weight were also recorded
Results:Women in the IG showed significantly (P ≤ 0.05) lower BMI and weight gain
during gestation, a trend towards lower triglyceride and caesarean sections and a sig-
nificant increase in postnatal attendance for metabolic assessment. Their newborns
showed significantly lower bodyweight and a trend towards fewermacrosomia.
Conclusions: These data suggest that our educational intervention plus management
changes induced a favourable impact on GDM outcomes for both mothers and off-
spring.
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1 INTRODUCTION
The prevalence of type 2 diabetes (T2D) grows ceaselessly worldwide,
mainly due to a combination of a population epidemiologic transition
towards aging, a more sedentary lifestyle, and a growingly earlier age
of onset.1 Although this phenomenon occurs globally, it mainly affects
developing countries.2 Simultaneously, the prevalence of gestational
diabetes (GDM), one of the most common complications of pregnancy,
has increased by over 30% in recent decades in several countries,3,4
thereby conforming an emerging worldwide epidemic.5
Globally, about 17% of pregnancies are affected by GDM, but its
incidence ranges from 1% to over 25% depending on diagnostic crite-
ria and maternal risk.6–11 Its prevalence in South and Central Amer-
ica is estimated at 11.2% (CI, 7.1-16.6%)9 with comparable statistics
reported for Argentina.12
GDM is associated with a higher risk of adverse health outcomes
during pregnancy and delivery for both mothers and babies. Women
with GDM have a higher risk of developing complications during preg-
nancy such as preeclampsia, instrumental deliveries, caesarean sec-
tion, postnatal DM and obesity, whereas their newborns have a higher
risk of developing short-term adverse events (macrosomia, neonatal
hypoglycaemia, respiratory distress syndrome and neonatal cardiac
dysfunction), as well as long-termmetabolic dysfunctions.13,14
This negative impact on the mother and offspring can be signifi-
cantly reduced by early diagnosis and adequate treatment combining
the adoption of a healthy lifestyle and, when needed, medication.15,16
Despite this heavy clinical impact, few studies have investigated its
economic burden: in the United States, the estimated cost of preg-
nancy with GDM was double that of normal pregnancy (a difference
of U$ 7803).17 In China, considering only the cost during the last ges-
tational trimester, the estimated difference in cost between a preg-
nancy with and without GDM was U$ 1008 (+95%); in 2015, its
total burden was U$ 2.92 billion (¥19.36 billion).18 Studies in different
European countries reported an increase ranging from 20% to 130%,
respectively.19–21 In Mexico, the care cost of a pregnancy with GDM
was 56.1% higher than that of a pregnancy without GDM.22 Such large
differences could be attributed to local healthcare systems, demog-
raphy and ethnic characteristics, as well as the application of differ-
ent methodologies. All of them, however, highlighted the considerable
economic burden and cost differences between pregnancies with and
without GDM.
Although it has not been clearly shown, we assume that the eco-
nomic burden in Argentina is similar. Therefore, in an attempt to
decrease this burden upon women with GDM and its economic impact
on the healthcare system, we have developed and implemented (a) an
educational approach that targets members of the healthcare team
(HCTM) at the primary/high complex care level and women with
GDMand (b) close contact/interaction between primary care level and
maternity hospitals to ensure that every woman with GDM is seen at
the appropriate high complexity level. Our study aims to assess the
impact of this educational approach and management changes on out-
comes for mothers and their offspring.
2 MATERIALS AND METHODS
Pregnant women with GDM consulting for medical care were sequen-
tially recruited between 2017 and 2019 in primary healthcare centres
in combination with participating high complexity maternity (HCM)
facilities. Participating HCM were one in the J. R. Vidal Hospital (Cor-
rientes Province) and another in the Argerich Hospital (Buenos Aires
City). Every pregnant woman diagnosed with GDM was immediately
referred to the HCM.
During this 2-year period, we recruited women with GDM at weeks
28-30 of pregnancy in a chronological sequential order. GDM patients
were diagnosed according to Latin American Diabetes Association
(ALAD), which is based on glycaemia values either at fasting or after
the universal oral glucose tolerance test performed on weeks 24-28 of
pregnancy.23 The recruited women attended follow-up visits from the
first clinical appointment and until they delivered the baby.
As exclusion criteria, we excludedwomen under 18 years of age due
to our law regarding underage patients,24 those with pre-GDM, those
who have previous history of serious obstetric complications as well as
those who declined to sign the informed consent.
All women with GDM who met the abovementioned conditions
and were recruited – in a sequential order – were as follows: Those
recruited from 2017 to mid-2018 were assigned to the control group
(CG), whereas those recruited from mid-2018 to 2019 were assigned
to the intervention group (IG). Applying this procedure, we recruited
263 and 432 women with GDM for the control and intervention
groups, respectively.
The women included in the CG received standardized care/routine
management and follow-up, including basic information on blood glu-
cosemonitoring and insulin injection when necessary.
For the IG, we developed and implemented an educational pro-
gramme, named EduGest, targeting different members of the HCTM
and women with GDM, especially adapted to each of these audi-
ences. Detailed descriptions of the later program have been already
reported.25 Briefly, starting at enrolment, we gave weekly small-group
interactive theoretical-practical courses that included basic physiolog-
ical concepts of the gestation process, foetal growth, normal vaginal
delivery and caesarean section, healthy maternal meal plan, physical
activities, breast-feeding and explanations of a model for insulin-self-
injection practices, blood glucose self-monitoring (SMBG) and data
interpretation. Participants were also given a manual summarizing
all these contents. These courses were delivered by pre-trained team
members –mainly nurses. It also provided educationalmaterial (Power
Point material and some models such as a perineum and vaginal canal
to simulate childbirth) to ensure their effectiveness.
The education program for the IG also includes physicians and
nurses who attended a separate, intensive course with specific
contents such as standards of diagnosis and prevention and treatment
of the disease. Evaluations of their knowledge were taken before and
after these courses using multiple-choice questionnaires. They also
provide training to enable healthcare professionals to update theQua-
liDiabGest, NutriQuidGest andWHO-5 registries. The QualiDiabGest
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includes clinical-metabolic and gestational events corresponding to
the mother and the foetus/newborn.25 The NutriQuidGest26 analyses
the patient’s self-reported food intake and calculates the essential
components and nutritional value. TheWHO-5 evaluates the patient’s
well-being and tendency to depression.27,28 Data were evaluated to
assess the impact of the educational programme on GDM outcomes.
With all these data, we addressed the evaluation of the impact of the
educational program onGDMoutcomes.
In both CG and IG groups, each woman’s clinical and metabolic
datawere registered using theQualiGest form, designed and validated
especially for the EduGest study.25 This form includes personal data
and obstetric history, body mass index (BMI), blood pressure, cardio-
vascular risk factors, fasting blood glucose (FBG), serum total choles-
terol and triglycerides. It also includes data on the woman’s obstet-
ric history, characteristics of delivery, preeclampsia, gestation-induced
hypertension and newborn’s bodyweight, aswell as the characteristics
of the deliverymethod employed.
Blood glucose and triglyceride assays were done following instruc-
tions of commercial kits. The total data recorded were loaded into a
single database for further statistical analyses.
2.1 Statistical analyses
Statistical analyses were done using the Statistical Package for
Social Sciences version 15 (SPSS Inc, Chicago, IL, USA). Descrip-
tive statistics are presented as percentages and mean ± standard
deviation (SD). Group comparisons for continuous variables were
determined by Student t-test and Mann-Whitney U test accord-
ing to the data distribution profile. We used two-way ANOVA to
assess differences between groups in increments in weight, BMI and
serum triglyceride of the pregnant women (CG vs IG) and differ-
ences between moments of measurement (baseline data vs the one
collected at the end of pregnancy). The Chi-squared statistic was
used to evaluate differences between proportions. Significance was
established at P≤ 0.05.
2.2 Ethical considerations
All study procedures were complied with the ethical standards of the
institutional research committee, theHelsinki Declaration of 1964 and
its subsequent modifications, or comparable ethical standards. The
study protocol was analyzed and approved by the Ethics Committee of
the Universidad Nacional del Nordeste (UNNE) (IRB Number: 27/16-
10819). All participants included in the study signed their correspond-
ing informed consent.
3 RESULTS
At the time of the first clinical appointment, clinical and obstetric
pregestational background information from the recruitedwomenwas
recorded as shown in Table 1. It shows that although women included
in the CGhave a background of lower percentage of obesity, they had a
larger percentage of previous macrosomic newborns. No other signifi-
cant difference was found comparing the other background factors.
Whenanalysing clinical andmetabolic variables recorded at the first
pregnancy consultation (Table 2), we saw that although we recruited
them only by a sequential chronological order, the only significant dif-
ference between CG and IG was gestational age (30.2 vs 28.9 weeks;
P ≤ 0.002) and FBG levels (100.6 ± 31.6 vs 92.2 ± 28.9 mg/dL;
P ≤ 0.000), respectively. These two values, however, indicate a GDM
diagnosis according to ADA criteria.27 In both groups, the diagnosis of
GDMwas confirmed byOral Glucose Tolerance Test (OGTT).
As an important detail, the QualiGest form records only the
woman’s body weight and height from these two measurements and
the software automatically calculated the BMI. Therefore, due to the
availability of these two basicmeasurements required by the system to
determine that parameter, we had BMI data only for 76% and 98% of
women from the CG and IG, respectively. These results might suggest
that even when data registry was not ideal, it improved in the IG.
At the end of the gestational/delivery period, women in the IG
had significantly lower BMI (33.5 ± 5.7 vs 35.8 ± 6.2 Kg/m2; P
≤ 0.003) and significantly less weight gain compared to the weight
recorded at the first clinical appointment (Table 3 and Figure 1). Con-
currently, the newborns in the IG showed significantly lower body
weight (3.377.9 ± 591.8 vs 3.484.1 ± 538.3 g; P ≤ 0.0021), a trend to
a lower percentage of macrosomia (12.0% vs 14.8%), a non-significant
but lower number of caesarean sections (56.0% vs 60.1%) and a trend
to lower serum triglyceride levels (250.1±92.6 vs 285.3±98.2mg/dL).
Also, newborn weight was significantly associated with the mother’s
weight gain in both the CG and the IG (r= 0.12, P< 0.025) (Figure 1).
The BMI calculated was 29% (CG) and 69% (IG), whereas triglyc-
eride levelswere3% (CG) and41% (IG). These differenceswere consid-
ered at the time of statistical evaluation, thereby suggesting a registry
improvement associated with the education process.
The number ofwomenwho attended reclassification 6months after
delivery was significantly greater in the IG (38% vs 2.7%; P ≤ 0.000)
(Table 3). In the former group, 76.8% had a normal OGTT, 19.5% had
prediabetes and 3.7% had already developed T2D. Due to the low per-
centage of cases in the CG (only sevenwomen attended), no consistent
statistical analysis could be done, but the values suggest that the group
had a poorer profile (57.1% normal OGTT and 42.9% T2D).
4 DISCUSSION
Our current IG results show the combination of several favourable out-
comes for both mothers and their offspring: a significantly lower BMI
and weight gain during the gestational period, a trend towards a lower
percentage of serum triglyceride and caesarean sections as well as a
significant increase in postnatal attendance to the medical appoint-
ment for metabolic assessment/reclassification.
The newborns had a significantly lower body weight associated
with a trend to a lower percentage of macrosomia. All together, these
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TABLE 1 Pregestational, clinical and obstetric background of the recruited pregnant women
Control group Intervention group




Hypertension (%) 4.9 263 3.0 432 0.193
Obesity (%) 15.6 263 25.0 432 0.003
Smoking (%) 2.7 263 3.0 432 0.790
Dyslipidaemia (%) 0.4 263 0.0 432 0.199
Obstetric history
Number of previous pregnancies
(mean± SD)
2.3± 2.0 258 2.0± 1.8 420 0.081
GDM in previous gestations (%) 10.5 209 13.5 347 0.296
Premature newborns (%) 8.5 235 6.8 426 0.424
Preeclampsia (%) 3.0 231 4.5 425 0.366
Family DMbackground (%) 46.6 251 52.9 423 0.176
Newbornwith>4 kg (%) 19.6 240 13.4 426 0.034
HIG in previous gestations (%) 7.2 236 5.2 425 0.289
Eclampsia (%) 0.4 231 0.7 426 0.669
Abbreviations: CVRF, cardiovascular risk factors; GDM, gestational diabetes; HIG, hypertension induced by gestation; DM, diabetes mellitus.
TABLE 2 Characteristics of pregnant women at the time of the first clinical appointment
Control group Intervention group
Parameter Mean± SD N Mean± SD N
P-value
(between groups)
Mother’s age at pregnancy outset (years) 30.8± 6.3 259 30.7± 6.5 427 0.819
Gestational age at the first consultation
(weeks)
30.2± 5.1 237 28.9± 4.8 396 0.002
Height (cm) 158.9± 6.5 221 158.0± 6.0 426 0.055
Weight (kg) 75.7± 17.4 229 74.6± 16.9 424 0.445
BMI (kg/m2) 29.9± 6.1 201 29.8± 6.2 423 0.908
SBP (mmHg) 107.5± 13.8 240 109.0± 13.2 419 0.184
DBP (mmHg) 67.5± 9.3 240 68.5± 9.6 419 0.160
FBG (mg/dL) 100.6± 31.6 220 92.2± 16.5 419 0.000
Triglyceride (mg/dL) 225.1± 91.8 46 236.2± 81.4 296 0.399
Total cholesterol (mg/dL) 229.2± 61.6 71 233.8± 48.0 368 0.481
Abbreviations: BMI, bodymass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose.
results suggest that our educational intervention combined with man-
agement changes (active interaction between primary care and special
maternity care) induced a favourable impact on several risk factors and
consequently onGDMoutcomes related to both themothers and their
offspring.
The lower BMI and weight gain during the gestational period
recorded for IGwomen have been associated with different decreased
risk ranges of adverse outcomes depending on pregestational
weight.29 This range went from 14.0 kg (underweight women) to less
than 6.0 kg for obesity grade 3 (BMI≥ 40 kg/m2).29 Gestational weight
gained outside this range was associated with low and moderate
adverse outcomes.30 A population-based study in the United States
of pregnant women with singleton hospital births between 2004 and
2013 found that both low and excess weight gain were associated
with severe adverse birth outcomes.31 In our case, newborn weight
was significantly associated with the mother’s weight gain (r = 0.12,
P< 0.025).
The combination of maternal BMI, excess gestational weight
gain and hyperglycaemia operates as a set of independent factors
promoting neonatal adiposity.32 This evidence supports the favourable
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TABLE 3 Outcomes at the end of the gestational/delivery period
Control group Intervention group
Data recorded Value N Value N
P-value
(between groups)
Delivery by caesarean (%) 60.1 238 56.0 423 0.311
Newborn (number) 1.2± 0.7 219 1.0± 0.1 421 0.001
Newborn
Capurro index (weeks) 38.6± 1.4 192 38.4± 1.9 422 0.214
Weight (g) 3.484.1± 538.3 243 3.377.9± 591.8 432 0.021
Macrosomia (%) 14.8 243 12.0 432 0.304
Other complications (%) 7.2 263 8.8 432 0.464
Maternal
Weight (kg) 88.7± 18.4 95 83.8± 15.4 304 0.011
BMI (kg/m2) 35.8± 6.2 77 33.5± 5.7 300 0.003
Triglyceride (mg/dL) 285.3± 98.2 7 250.1± 92.6 175 0.361
Complications (%) 8.7 263 7.9 432 0.684
Postpartum reclassification (%) 2.7 263 38.0 432 0.000














F i gu re 1 Increase in BMI (baseline vs at the end of pregnancy)
pathogenic role of lower weight gain observed in our IG women. With
the same reasoning, a recent report strongly suggests that early GDM
screening and diagnosis may be beneficial for tempering gestational
weight gain by prescribing and monitoring treatment early in the
pregnancy: this program includes the adoption of a healthy lifestyle
(meal planning and weight management), as first-line treatment for
GDM together with initiating SMBG.33,34
A trend of decreased triglyceride was another risk factor ascribed
to our educational intervention: though during pregnancy an increase
of serum triglyceride occurs normally as a compensatory mechanism
to cope with increased demand for metabolic substrates,35 it has
been proposed that impairment of lipid metabolism rather than solely
hyperglycaemia is the factor that increases the risk for macroso-
mia in GDM.36 Our recent publication which studied the frequency
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and pathogenesis of macrosomia in mothers with GDM supports
this hypothesis.37 Although no clear normal cut-off values for serum
triglyceride are available for our local population, the lower values
recorded in our IG women suggest that they may favour the signifi-
cantly lower body weight and the lower trend to macrosomia of the
offspring currently reported. We are at the moment trying to settle
the triglyceride cut-off value for each gestation trimester to overcome
such lack of information.
Despite the large pathogenic role of triglyceride in undesirable
GDM outcomes, our data show that their measurement is neither sys-
tematically prescribed nor fully and systematically recorded. How to
change this behaviour may be an excellent area for further research.
Outcomes improvement in our IG could be partly ascribed to
the women’s adherence to the prescription of a healthy life style;
its efficacy concords with previous reports establishing that preven-
tion/treatment of GDM must start with dietary and lifestyle advice,
associated with metformin or insulin when the former strategy fails to
reach glucose target values. Diabetes education provided to IG might
be a prime factor in the induction of this healthy behaviour and the con-
sequent reduction of the risk of having big babies.38
The efficiency of the education strategy currently implemented is
further supported by the conclusions of the Cochrane meta-analysis,
which assures that lifestyle interventions are the primary therapeutic
strategy as well as self-monitoring of blood glucose levels.39 Its suc-
cess, however, requires trained personnel to provide optimal educa-
tion andmanagement support such as we implemented in our EduGest
study.
Low-quality evidence suggests that women receiving these educa-
tional interventions may have more probability of achieving weight
goals than those receiving the customary care or only dietary advice.
For the infant, moderate-quality evidence shows that lifestyle inter-
ventions yield a reduced risk of births with large-for-gestational-age
babies and reduced adiposity compared to usual-care or dietary-
advice-only babies. On another front, little is known about the
cost-effectiveness of these interventions on GDM outcomes for
mothers and/or their offspring.40 This point merits further studies for
its assessment and to get stronger evidence of its efficacy.
Postpartum attendance for metabolic reclassification was another
successful goal of our intervention: 164 versus seven cases in the IG
and CG, respectively. The low attendance observed in the CG was not
completely unexpected, because it has been reported that after deliv-
ery, women who have had a GDM face difficulties for attending glu-
cose testing postpartum and long-term control visits. These difficulties
include fears concerning the risk of developing diabetes and other fac-
tors as well. Previous reports have shown that education regarding the
risk of developing T2D after having GDM, provided during and after
pregnancy, would lower the barriers against testing, thereby enabling
earlier diagnosis/treatment management of diabetes and improving
long-term outcomes.40,41 These findings consequently lend further
support to our current improvement of postpartum consultations in
the IG.
Although we have too few cases to reach a sustainable conclusion,
the large difference in percentage of Normal Glucose Tolerance (NGT)
(78.6% vs 57.1%) and of T2D (3.7% vs 42.6%) in the IG and CG, respec-
tively, would suggest a favourable impact of our intervention on these
results. This suggestion merits further studies to prove the real value
of this assumption.
All our results could be ascribed to the educative strategy employed,
thereby confirming its effectiveness. In this regard, we initially assume
that GDM results from β-cell failure to cope with gestational insulin
resistance and that its treatment attempts to prevent/decrease
adverse pregnancy outcomes. Consequently, we share and support
other authors’ conclusion that education is the cornerstone of GDM
management, and that well-trained members of the HCTM are the
most effective personnel for its implementation.42
They also support the hypothesis that this type of intervention
implemented at the primary care level closely associated with HCM
facilities at an early stage, that is before the pregnancy develops
GDM, would enhance the chances for both effective gestation control
and post-delivery surveillance to implement preventive care, thereby
reducing the risk of undetected early-onset T2D.43 Furthermore, edu-
cation given and supported by diabetes peers is associated with many
benefits in relation to clinical, behavioural, and psychosocial outcomes.
Consequently, when feasible, peer support could be included in order
to reap its many potential benefits and cost-effectiveness.44
Regarding the future, we might consider that all the above
education-induced beneficial effects were obtained by initiating its
implementation around the 29-30 gestational weeks; therefore, the
results could presumably be significantly improved when educa-
tion is applied at an earlier stage: ideally, in the first trimester of
gestation.
Although our results provide evidence of the improvement of GDM
outcomes ascribed to educational intervention, they should be consid-
ered with caution due to several weaknesses, namely (a) BMI differ-
ences at the end of the gestational period were not obtained/recorded
for all the participants, (b) serum triglyceride levels were mea-
sured/recorded at that period only for less than 50% of the partici-
pants, (c) many of our improvements showed a trend to rather than
a significant difference in favour of the IG and (d) our physicians do
not spend much time or dedicate careful attention to completely fill
out the patient’s records; we might reinforce recommendations in our
educational program to cope with this problem as suggested by other
authors.45 Implementation of electronic clinical records might also
help to overcome this deficiency.46
As an aditional limitation, although we have explored food intake
(NutriGest) and psychological impact (WHO-5) of GDM, we have
presently not described/analysed these results. Theymerit, however, a
deep analysis to their respective role within the education process for
a further proximal publication.
Notwithstanding, the consistency of the current data suggests the
favourable impact of the integral educational process implemented for
the HCTMmembers and the womenwith GDMdiabetes.
In conclusion, our results suggest that education provided to all
the actors involved in the gestation process (women with GDM, mem-
bers of the HCTM and a well-trained education team), in an integrated
combination of primary care level and HCM facilities, is an effective
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approach to cope with the socioeconomic burden of the disease both
at present and in the long term.
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